Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026
Globe Newswire (Wed, 8-Apr 4:05 PM ET)
Managed care rebounds after Medicare rate decision
Seeking Alpha News (Tue, 7-Apr 1:39 PM ET)
Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership
Globe Newswire (Tue, 7-Apr 8:30 AM ET)
Globe Newswire (Wed, 1-Apr 8:30 AM ET)
Globe Newswire (Thu, 19-Mar 8:30 AM ET)
Globe Newswire (Tue, 10-Mar 8:30 AM ET)
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
Globe Newswire (Wed, 4-Mar 8:30 AM ET)
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
Globe Newswire (Thu, 26-Feb 4:05 PM ET)
Clover Health to Participate in Upcoming Leerink 2026 Global Healthcare Conference
Globe Newswire (Tue, 17-Feb 4:05 PM ET)
Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Globe Newswire (Thu, 29-Jan 4:05 PM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of April 10, 2026, CLOV stock price climbed to $1.92 with 373,768 million shares trading.
CLOV has a beta of 0.83, meaning it tends to be less sensitive to market movements. CLOV has a correlation of 0.03 to the broad based SPY ETF.
CLOV has a market cap of $992.02 million. This is considered a Small Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $488 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $18 million and missed earnings estimates by -$.03.
In the last 3 years, CLOV traded as high as $4.87 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CLOV has underperformed the market in the last year with a return of -47.1%, while the SPY ETF gained +25.6%. In the last 3 month period, CLOV fell short of the market, returning -26.2%, while SPY returned -1.5%. However, in the most recent 2 weeks CLOV has outperformed the stock market by returning +6.7%, while SPY returned +5.7%.
CLOV support price is $1.84 and resistance is $1.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV shares will trade within this expected range on the day.